Botulinum Toxin Therapy in Hidradenitis Suppurativa

Study overview

This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Collaborators and Investigators

University of Massachusetts, Worcester,

Sarah K Whitley, MD PhD, PRINCIPAL_INVESTIGATOR, Assistant Professor of Dermatology

Study Record Dates

2028-04-30